diabetes
HIV, diabetes and immune cells in fat
Mar. 18, 2021—In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.
Targeting glucagon action in diabetes
Mar. 4, 2021—Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy.
Gene variant and glucose metabolism
Feb. 18, 2021—Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study.
Early research shows promise for therapeutics that delay Type 2 Diabetes
Jan. 12, 2021—Discovering the mechanism behind cell behavior that is a hallmark of type 2 diabetes, Vanderbilt researchers move closer to treatments for the disease, which affects 34 million Americans.
Vanderbilt Diabetes Center seeks pilot and feasibility proposals to study interaction of SARS-CoV-2, diabetes
Dec. 16, 2020—The Vanderbilt Diabetes Center, the NIH-funded Diabetes Research and Training Center, and the NIH-funded Center for Diabetes Translational Research seek pilot and feasibility proposals to study the interaction of SARS-CoV-2/COVID-19 and diabetes.
Study sheds light on diabetes and COVID interaction
Dec. 10, 2020—COVID-19 has been linked to cases of new-onset diabetes, diabetes-related emergencies and a higher death rate among diabetes patients.
A cohort for type 2 diabetes studies
Nov. 17, 2020—A study group of more than 600,000 patients with type 2 diabetes, identified from electronic medical records in the PCORnet national research network, could be valuable for assessing the safety of type 2 diabetes drugs.
New treatment for a rare obesity
Nov. 3, 2020—Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity.
Clue to diabetic kidney disease
Oct. 5, 2020—Vanderbilt researchers have identified a signaling pathway that promotes kidney fibrosis in patients with diabetes — and that could be targeted with an existing approved medication.
Go for the Gold: How to determine your risk for diabetes
Sep. 11, 2020—One in nine American adults has diabetes, and one in three has pre-diabetes. Prevention and early intervention can decrease the risk of complications down the road.
Vanderbilt historian explores impact of racism, classism on understanding diabetes
Aug. 19, 2020—Research by Vanderbilt history professor Arleen Tuchman on the cultural history of diabetes offers important lessons for other public health challenges, including COVID-19.
Keeping beta cells “fit”
Jul. 9, 2020—Vanderbilt cell biologists are defining the factors that help beta cells in the pancreas stay healthy, secrete insulin and prevent diabetes initiation and progression.